Green Cross, Institutional Investors Net Buy 215,223 Shares in Last 5 Days... Stock Price 385,000 KRW (+0.65%)

As of 12:31 PM on the 5th, Green Cross is trading at 385,000 KRW, up 0.65% from the previous day. The trading volume is 651,692 shares, which is 23.59% of the previous day's volume. Green Cross is known as a pharmaceutical company specializing in blood products and vaccines.

On November 5th, Jin Heung-guk, a researcher at Korea Investment & Securities, stated, "With the contract manufacturing of COVID-19 vaccines, an additional operating profit of 600 billion KRW is expected next year. By the end of the year, momentum for the IVIG FDA BLA submission is also anticipated. Starting from 2023, sales of IVIG to the U.S. will begin, generating operating cash flow close to 400 billion KRW annually until 2025, making it promising from a long-term investment perspective. In the short term, the IVIG BLA submission and the signing of the main contract for the COVID-19 vaccine require continuous attention despite the short-term surge in stock price." He set the target price for Green Cross at 500,000 KRW.

Over the past five days, individual investors have net sold 195,345 shares of Green Cross, while foreigners and institutions have net bought 28,346 shares and 215,223 shares, respectively.

※ Source: AI Investment Assistant AI Rassiro

※ This article was generated in real-time by an automated article generation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.

This content was produced with the assistance of AI translation services.